Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avian infectious coryza trivalent inactivated vaccine (Youbang Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Youbang Pharmaceutical
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The avian infectious coryza trivalent inactivated vaccine, developed by Youbang Pharmaceutical, is a veterinary biologic designed to prevent infectious coryza in poultry. Infectious coryza is an acute respiratory disease caused by the bacterium *Avibacterium paragallinarum*, characterized by symptoms such as nasal discharge, facial edema, and conjunctivitis. This trivalent vaccine contains inactivated bacterial strains representing the three primary Page serogroups (A, B, and C), providing broad-spectrum protective immunity against the diverse strains of the pathogen. It is formulated as an inactivated (killed) bacterial vaccine and is approved for use in chickens to reduce the clinical impact and spread of the disease within flocks.
- Other names
- 鸡传染性鼻炎(A型+B型+C型)三价灭活疫苗Avian infectious coryza (serotypes A, B, and C) trivalent inactivated vaccineAvibacterium paragallinarum (serogroups A, B, C) inactivated vaccine
Beyond the preview
Go deeper on Avian infectious coryza trivalent inactivated vaccine (Youbang Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avian infectious coryza trivalent inactivated vaccine (Youbang Pharmaceutical).